Evidence map›Paper›PMID 28574929›Full record

ArticleInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society2017

Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer.

Rudy S Suidan, Weiguo He, Charlotte C Sun, Hui Zhao, Lois M Ramondetta, Brian D Badgwell, Diane C Bodurka, Karen H Lu, Sharon H Giordano, Larissa A Meyer

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of gynecological cancer : official journal of the International Gynecological Cancer Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Rudy S Suidan*Division of Surgery, Department of Gynecologic Oncology and Reproductive Medicine; †Department of Health Services Research; and ‡Division of Surgery, Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Weiguo He
Charlotte C Sun
Hui Zhao
Lois M Ramondetta
Brian D Badgwell
Diane C Bodurka
Karen H Lu
Sharon H Giordano
Larissa A Meyer
Gynecologic Oncology Group · USDepartment of Health Services · NPThe University of Texas MD Anderson Cancer Center · US

Funding

Training of Academic Gynecologic OncologistsT32CA101642 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI ANIL K SOOD, Kathleen Schmeler · 2005 to 2026
$9.2M
Health Services Career Development: Improving Medical Decisions in Ovarian CancerK07CA201013 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI MEYER, LARISSA ALEJANDRA · 2016 to 2020
$853k
NCI NIH HHS K07 CA201013NCI NIH HHS T32 CA101642
6 · The paper itself

Abstract

objectiveThe aim of this study was to assess treatment patterns, outcomes, and costs for bowel obstruction in ovarian cancer. METHODS/MATERIALS: All patients with stage II to IV ovarian cancer who were admitted for bowel obstruction greater than or equal to 6 months after cancer diagnosis from 2000 to 2011 were identified from the Surveillance, Epidemiology, and End Results registry-Medicare database. Management strategies and outcomes of bowel obstruction were compared.

resultsAmong 1397 women with bowel obstruction, 562 (40%) underwent surgery, and 154 (11%) had a gastrostomy or jejunostomy (G/J) tube placed. Thirty-four percent of patients who underwent surgery subsequently received chemotherapy, compared with 8% of those managed with a G/J tube (odds ratio, 4.8; 95% confidence interval [CI], 2.7-8.8). Thirty-day complications were higher for patients in the surgery group compared with those in the tube group (69% vs 46%; odds ratio, 2.5; 95% CI, 1.8-3.7), as were mean adjusted 30-day total costs ($28,872 vs $18,528, P < 0.001). Median survival was greater for women who underwent surgery compared with those who had a G/J tube (5.3 vs 1.2 months; adjusted hazard ratio, 0.31; 95% CI, 0.25-0.38). The median survival of patients in whom surgical correction failed and required G/J tube placement during the same inpatient admission was 2.6 months. Women who received postintervention chemotherapy had improved survival compared with those who did not in both the surgery (17.0 vs 2.8 months, P < 0.001) and G/J tube (5.7 vs 1.0 months, P < 0.001) groups.

conclusionsIn women with ovarian cancer who develop bowel obstruction, surgery may benefit a subset of patients, likely related to the ability to receive subsequent chemotherapy. Efforts to identify those who derive no benefit may reduce unnecessary laparotomy, along with its associated complications and costs. Given this population's limited survival, patient preferences should be evaluated in future studies assessing the management of bowel obstruction.

Indexed as

AgedAged, 80 and overChemotherapy, AdjuvantCohort StudiesFemaleHealth Care CostsHumansIntestinal ObstructionNeoplasm StagingOvarian NeoplasmsRetrospective StudiesSEER ProgramUnited States

Identifiers

PMID28574929
PMCPMC5862427
OpenAlexW2621021132

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.